News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Thursday, November 27, 2025BeOne Medicines Ltd has announced that the US Food and Drug Administration FDA has accepted and granted Priority Review to the New Drug Application NDA for sonrotoclax This nextgeneration BCL inhibitor
Teva Receives European Commission Approval for PONLIMSI® and DEGEVMA®, Biosimilars to Prolia® and Xgeva®
Wednesday, November 26, 2025Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd has received marketing authorisation from the European Commission EC for its two denosumab biosimilars PONLIMSI a biosimilar to Prolia
Bristol Myers Squibb receives European Commission approval to expand use of CAR T cell therapy Breyanzi for relapsed or refractory mantle cell lymphoma
Tuesday, November 25, 2025Bristol Myers Squibb announced that the European Commission EC has granted approval to Breyanzi lisocabtagene maraleucel lisocel a CDdirected chimeric antigen receptor CAR T cell therapy for the treatment of adult patients with relapsed or refractory...
Harbour BioMed strengthens global collaboration with AstraZeneca to advance next-generation oncology biotherapeutics
Tuesday, November 25, 2025Harbour BioMeda global biopharmaceutical company focused on developing novel antibody therapies for immunology and oncology has announced progress and expansion in its strategic collaboration with AstraZeneca first launched
Harbour BioMed Advances Global Strategic Collaboration With AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
Monday, November 24, 2025Harbour BioMed and AstraZeneca have advanced their European strategic partnership to focus on nextgeneration antibody therapeutics in oncology targeting accelerated discovery development and commercialization of biotherapeutics across the region
GSK and LTZ Form Strategic Collaboration to Advance Novel Myeloid Cell Engagers in Oncology
Friday, November 21, 2025GSK plc and LTZ Therapeutics an immunotherapyfocused biotechnology company in Redwood City California have entered a strategic research collaboration to develop a new class of cancer treatments known as myeloid cell engagers MCEs
AGC Biologics and Repair Biotechnologies Form Partnership to Advance Novel mRNA Therapy Targeting Atherosclerosis
Friday, November 21, 2025AGC Biologics has announced a new partnership with Repair Biotechnologies to develop and manufacture an innovative mRNA therapy aimed at reducing atherosclerotic plaque a major cause of heart attacks and strokes
European Commission Grants Conditional Marketing Authorisation for Roche's Lunsumio Subcutaneous for Relapsed or Refractory Follicular Lymphoma
Wednesday, November 19, 2025Roche secures conditional EC authorisation for Lunsumio subcutaneous a new rapidadministered treatment for relapsed or refractory follicular lymphoma in Europe
Merus and Halozyme Sign Global Agreement to Develop Subcutaneous Version of Petosemtamab
Tuesday, November 18, 2025Merus NV an oncology company focused on multispecific antibodies and antibodydrug conjugates has entered into a global nonexclusive collaboration and licence agreement with Halozyme Therapeutics a specialist in subcutaneous
Sofinnova Partners Closes €650M Flagship Fund to Accelerate European Biotech and Medtech Innovation
Tuesday, November 18, 2025Sofinnova Partners has closed its million Sofinnova Capital XI fund targeting earlystage biotech and medtech companies across Europe and the US
